7.1 SENIOR LEADERSHIP 7.1.1 DIRECTOR: DOUGLAS YEE, M.D. (50%, or 6 cal mos) Douglas Yee, M.D. was named Cancer Center Director March, 2007. Dr. Yee holds the Tickle Family Land Grant Chair in Breast Cancer and Professor of Medicine and Pharmacology. As Director, Dr. Yee reports to the Senior Vice President for Health Sciences, Dr. Frank Cerra. Dr. Yee, as director, has responsibility and authority for development and implementation of the Cancer Center's research mission, strategic planning, faculty recruitment, resource development, leadership: appointments, and facilities. As noted in the 'Essential Characteristics' section, his goal for the Cancer Center is to impact cancer outcomes with the knowledge gained in population and basic science research. Facilitating this translation is a focus on the Cancer Center, and the Senior Leadership was selected by Dr. Yee to maximize these efforts. Dr. Yee was recruited to the University of Minnesota Cancer Center in 1999 from the University of Texas Health Science Center at San Antonio where he was the Leader of the Growth Factor program in the San Antonio Cancer Institute, a NCI-designated comprehensive cancer center. He became the leader of the Breast Cancer Program in Minnesota. Dr. Yee's clinical interests are in breast cancer. He has focused his laboratory work on the growth regulation of cancer cells by the insulin-like growth factors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA077598-14S2
Application #
8533457
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
14
Fiscal Year
2012
Total Cost
$1,776
Indirect Cost
$600
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Sarver, Aaron L; Murray, Collin D; Temiz, Nuri A et al. (2016) MYC and PVT1 synergize to regulate RSPO1 levels in breast cancer. Cell Cycle 15:881-5
Diep, Caroline H; Knutson, Todd P; Lange, Carol A (2016) Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming. Mol Cancer Res 14:141-62
Yun, Young Sung; Kim, Kwan Hyun; Tschida, Barbara et al. (2016) mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress. Mol Cell 61:625-39
Yan, Y; Hanse, E A; Stedman, K et al. (2016) Transcription factor C/EBP-β induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells. Cell Death Differ 23:1232-42
Beura, Lalit K; Hamilton, Sara E; Bi, Kevin et al. (2016) Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532:512-6
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87
Struntz, Nicholas B; Harki, Daniel A (2016) Catch and Release DNA Decoys: Capture and Photochemical Dissociation of NF-κB Transcription Factors. ACS Chem Biol 11:1631-8
Knorr, David A; Wang, Hongbo; Aurora, Mukta et al. (2016) Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 22:825-33
Glasgow, Michelle; Vogel, Rachel Isaksson; Burgart, Jennifer et al. (2016) Long term follow-up of a phase II trial of multimodal therapy given in a ""sandwich"" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol Res Pract 3:6
Felices, Martin; Lenvik, Todd R; Davis, Zachary B et al. (2016) Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells. Methods Mol Biol 1441:333-46

Showing the most recent 10 out of 763 publications